Vericel swings to operating profit, adds up to $200M buyback; revenue up 22.5%

Filed July 30, 2026 · Period ending June 30, 2026 · Compared to 10-Q Jul 31, 2025 · ~1 min read

Key Changes

• high

  Subsequent event: In July 2026, the Company’s Board of Directors authorized the repurchase of up to $200.0 million of the Company’s common stock, with no expiration date. The authorization allows for repurchases to be made in the open…

  Notes: Subsequent Events verify on EDGAR →
• high

  Revenue rose 22.5% to $77.5M in Q2 2026, and the company swung to operating income of $434,000 from a $2.0M loss a year ago.

  MD&A: Results of Operations verify on EDGAR →
• high

  Board authorized a up to $200M share repurchase program in July 2026, with no expiration date.

  Subsequent Events verify on EDGAR →